For instance, manipulation of GSK-3β using targeted therapies (e.g., antisense oligonucleotides that inhibit GSK-3β in high-expressing strains or drugs that target the pathway) is needed to study changes in methionine expression and AD progression. This evidence concerns the gene GSK3B and Alzheimer disease.